What is Mydecine Innovations?

Mydecine Innovations Group is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.

At the heart of Mydecine’s core philosophy is that psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply. Mydecine has also successfully completed multiple acquisitions since its inception.

When was Mydecine founded?

The Company was incorporated under the Business Corporations Act (British Columbia) on September 27, 2013, under the name 0981624 B.C. Ltd. The Company subsequently changed its name to New Age Farm Inc. on April 10, 2014, to New Age Brands Inc. on November 14, 2018, to NewLeaf Brands Inc. on April 2, 2019 and to Mydecine Innovations Group Inc. on June 5, 2020.

Where is Mydecine headquartered?

Mydecine is headquarted in Vancouver, BC.

Who are Mydecine’s top executives?

Management team

When did Mydecine become a public company?

Mydecine became listed on CSE on August 18, 2014, the Company was uplisted to the NEO Exchange on March 23, 2021.

What exchange does the stock trade on and what is the stock ticker symbol?

Mydecine trades on the NEO Exchange (“NEO”) under the ticker symbol “MYCO”

How do I invest in Mydecine?

You can purchase shares in the Company through a registered broker-dealer of your choice. You cannot purchase units directly from the Company. For information about investing in stocks, you may want to consult a financial professional to explain to you the risks and suitability when investing.

Does Mydecine offer a Direct Stock Purchase Plan (DSPP or DRIP)?

We do not offer a direct stock purchase or dividend reinvestment program.

Does Mydecine pay a dividend?

Mydecine does not anticipate paying any cash dividends in the foreseeable future.

When is the Company's fiscal year end?

Our fiscal year end is December 31.

Who is Mydecine's independent auditor?

MNP LLP

Address: Suite 2000, 330 5th Ave. S.W., Calgary, AB, T2P 0L4

Email: Maruf Raza – maruf.raza@mnp.ca

Tel: +1 403-444-0150

Who is Mydecine’s transfer agent?

National Securities Administrators Ltd

Where can I get a copy of materials filed?

Our public securities filings are available on www.sedar.com.

Do you have another question that hasn't been answered?

Please submit investor questions here.